Spots Global Cancer Trial Database for urinary bladder neoplasms
Every month we try and update this database with for urinary bladder neoplasms cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cabozantinib for Advanced Urothelial Cancer | NCT01688999 | Urothelial Carc... Urethral Neopla... Urinary Bladder... Kidney Neoplasm... | Cabozantinib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment | NCT03672240 | Non-Muscle Inva... | APL-1202 | 18 Years - 99 Years | AsierisPharma | |
| A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder | NCT04919512 | Urinary Bladder... | TAR-200 Cetrelimab | 18 Years - | Janssen Research & Development, LLC | |
| Prospective Sample Collection for Cancer of Bladder | NCT03973671 | Urinary Bladder... | 18 Years - 90 Years | Universitaire Ziekenhuizen KU Leuven | ||
| A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102 | NCT04109092 | Urinary Bladder... | E7766 | 18 Years - | Eisai Inc. | |
| A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder | NCT05742867 | Urinary Bladder... | 18 Years - | Bristol-Myers Squibb | ||
| Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers | NCT06087016 | Urinary Bladder... | Urine vibration... | 18 Years - | CHU de Reims | |
| Peri-operative Aspirin Continuation Versus Discontinuation | NCT02350543 | Hematuria Urinary Bladder... | Aspirin | 18 Years - | Rabin Medical Center | |
| Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers | NCT06087016 | Urinary Bladder... | Urine vibration... | 18 Years - | CHU de Reims | |
| A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) | NCT04172675 | Urinary Bladder... | Erdafitinib Investigator Ch... Investigator Ch... | 18 Years - | Janssen Research & Development, LLC | |
| Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder | NCT06289283 | Urinary Bladder... Microtia | Urine samples a... | 18 Years - | Theodor Bilharz Research Institute | |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer | NCT01200992 | Bladder Neoplas... Neoplasm Recurr... Transitional Ce... Carcinoma in Si... Mycobacterium | EN3348 Mitomycin C | 18 Years - | Bioniche Life Sciences Inc. | |
| Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment | NCT03672240 | Non-Muscle Inva... | APL-1202 | 18 Years - 99 Years | AsierisPharma | |
| A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy | NCT03404791 | Urinary Bladder... | TAR-200 | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05014139 | Urinary Bladder... Carcinoma in Si... Carcinoma Trans... Non-muscle Inva... NMIBC | Enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | NCT02788201 | Urothelial Carc... Bladder Cancer Urinary Bladder... | 75 approved age... COXEN | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder | NCT05742867 | Urinary Bladder... | 18 Years - | Bristol-Myers Squibb | ||
| A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder | NCT03519256 | Urinary Bladder... | Nivolumab BCG BMS-986205 | 18 Years - | Bristol-Myers Squibb | |
| FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer | NCT06421142 | Urinary Bladder... | imaging examina... | 18 Years - 80 Years | First Affiliated Hospital of Fujian Medical University | |
| Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer | NCT00384891 | Urinary Bladder... Urinary Bladder... Urinary Bladder... Malignant Tumor... Urologic Diseas... Urologic Neopla... Neoplasms Neoplasms by Si... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| Peri-operative Aspirin Continuation Versus Discontinuation | NCT02350543 | Hematuria Urinary Bladder... | Aspirin | 18 Years - | Rabin Medical Center | |
| Effect of PEEP on Arterial Oxygen Partial Pressure in Elderly Patients With Lithotomy Position Using LMA Supreme™ | NCT03390127 | Urinary Bladder... Prostatic Neopl... | PEEP | 65 Years - 79 Years | Asan Medical Center | |
| LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer | NCT02612194 | Urinary Bladder... Ureteral Neopla... Urethral Neopla... | Crizotinib | 18 Years - | Wake Forest University Health Sciences | |
| A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer | NCT03661320 | Urinary Bladder... Muscle-Invasive... | Nivolumab Gemcitabine Cisplatin | 18 Years - | Bristol-Myers Squibb | |
| Impacts of Different Pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surgery | NCT02600481 | Prostatic Neopl... Urinary Bladder... | low-pressure pn... standard-pressu... | 18 Years - 80 Years | Huadong Hospital | |
| A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer | NCT05567185 | Urinary Bladder... Receptors, Fibr... | Erdafitinib Int... | 18 Years - | Janssen Pharmaceutical K.K. | |
| Effect of Head Elevation on LMA Insertion | NCT04229862 | Laryngeal Masks Urinary Bladder... | Laryngeal mask ... | 20 Years - 79 Years | Asan Medical Center | |
| GreenBladder - Early Detection of Bladder Cancer in Residents in Greenland Using a Urinary Marker and a Mobile Cystoscopy Unit | NCT06281691 | Urinary Bladder... | Xpert® Bladder ... | 18 Years - | Aarhus University Hospital | |
| Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After Cystectomy | NCT01435356 | Urinary Bladder... | recMAGE-A3 + AS... Placebo | 18 Years - | European Association of Urology Research Foundation | |
| Molecular Biosensors for Detection of Bladder Cancer | NCT02957370 | Urinary Bladder... | 18 Years - | University of California, Irvine | ||
| Effect of Head Elevation on LMA Insertion | NCT04229862 | Laryngeal Masks Urinary Bladder... | Laryngeal mask ... | 20 Years - 79 Years | Asan Medical Center | |
| FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer | NCT06421142 | Urinary Bladder... | imaging examina... | 18 Years - 80 Years | First Affiliated Hospital of Fujian Medical University | |
| A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | NCT04640623 | Urinary Bladder... | TAR-200 Cetrelimab | 18 Years - | Janssen Research & Development, LLC | |
| Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment | NCT00710970 | Urinary Bladder... | Tamoxifen | 18 Years - | Baylor College of Medicine | |
| Impacts of Different Pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surgery | NCT02600481 | Prostatic Neopl... Urinary Bladder... | low-pressure pn... standard-pressu... | 18 Years - 80 Years | Huadong Hospital | |
| A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) | NCT03459846 | Urinary Bladder... | Durvalumab Olaparib Placebo | 18 Years - 130 Years | AstraZeneca | |
| Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma | NCT02619253 | Renal Cell Carc... Urinary Bladder... | Pembrolizumab Vorinostat | 18 Years - | Indiana University | |
| Study Comparing Open Radical Cystectomy With Robot-assisted Cystectomy in Patients With Bladder Cancer | NCT03977831 | Urinary Bladder... | Radical Cystect... | 18 Years - | Rigshospitalet, Denmark | |
| TURBt With Adjuvant Cryoablation to Treat Bladder Cancer | NCT02760953 | Urinary Bladder... | Cryoablation Epirubicin | 18 Years - 85 Years | Huashan Hospital | |
| Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer | NCT03081858 | Bladder Cancer ... Non-Muscle Inva... Bladder Cancer Urinary Bladder Transitional Ce... Urinary Bladder... Urologic Neopla... Urogenital Neop... Urinary Bladder... Urologic Diseas... | TSD-001 | 18 Years - 85 Years | Lipac Oncology LLC | |
| Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients | NCT05068180 | Stomach Neoplas... Colonic Neoplas... Rectal Neoplasm... Sigmoid Neoplas... Liver Neoplasms Kidney Neoplasm... Urinary Bladder... Prostatic Neopl... Osteoarthropath... Fractures, Bone Gynecologic Can... | low-dose neurol... Placebo | 65 Years - 85 Years | RenJi Hospital | |
| Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms | NCT02430623 | Urinary Bladder... | Irreversible el... NanoKnife | - | Fuda Cancer Hospital, Guangzhou | |
| Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer | NCT05687721 | Advanced Urothe... | copanlisib Avelumab | 18 Years - | VA Office of Research and Development | |
| CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer | NCT03933826 | Bladder Cancer Cancer of the B... Non-muscle Inva... | 18 Years - | University of Washington | ||
| A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer | NCT03288545 | Carcinoma, Tran... Urinary Bladder... Urologic Neopla... Renal Pelvis Ne... Urothelial Canc... Ureteral Neopla... Urethral Neopla... | enfortumab vedo... pembrolizumab cisplatin carboplatin gemcitabine | 18 Years - | Astellas Pharma Inc | |
| The Bladder Instillation Comparison Study | NCT02695771 | Urinary Bladder... | Mitomycin C Gemcitabine | 18 Years - | Spectrum Health Hospitals | |
| A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | NCT05014139 | Urinary Bladder... Carcinoma in Si... Carcinoma Trans... Non-muscle Inva... NMIBC | Enfortumab vedo... | 18 Years - | Astellas Pharma Inc | |
| Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01) | NCT04922047 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Antineoplastic ... Urinary Bladder... Tislelizumab An... | tislelizumab an... | 18 Years - 75 Years | RenJi Hospital | |
| CIK in Treating Patients With Bladder Cancer | NCT02489890 | Urinary Bladder... | Cytokine-induce... | 18 Years - 80 Years | The First People's Hospital of Changzhou | |
| Postoperative Quality of Recovery After Transurethral Resection of the Bladder | NCT02534623 | Urinary Bladder... Transurethral R... Postoperative R... | Spinal anesthes... General anesthe... bupivacaine fentanyl propofol sevoflurane | 18 Years - 80 Years | General Hospital Zadar | |
| Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer | NCT01200992 | Bladder Neoplas... Neoplasm Recurr... Transitional Ce... Carcinoma in Si... Mycobacterium | EN3348 Mitomycin C | 18 Years - | Bioniche Life Sciences Inc. | |
| Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | NCT01310803 | Carcinoma in Si... Transitional Ce... Non-muscle Inva... | VALSTAR - Maint... No Maintenance ... | 18 Years - | Endo Pharmaceuticals | |
| Propofol and Sevoflurane for Catheter-Related Bladder Discomfort | NCT02252445 | Catheter Site D... Complications Anesthesia Urinary Bladder... | Propofol Sevoflurane | 19 Years - 80 Years | Seoul National University Hospital | |
| Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients | NCT05068180 | Stomach Neoplas... Colonic Neoplas... Rectal Neoplasm... Sigmoid Neoplas... Liver Neoplasms Kidney Neoplasm... Urinary Bladder... Prostatic Neopl... Osteoarthropath... Fractures, Bone Gynecologic Can... | low-dose neurol... Placebo | 65 Years - 85 Years | RenJi Hospital | |
| Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort | NCT02228473 | Catheter Site D... Complications Anesthesia Urinary Bladder... | Glycopyrrolate Atropine | 19 Years - 80 Years | Seoul National University Hospital | |
| Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma | NCT02788201 | Urothelial Carc... Bladder Cancer Urinary Bladder... | 75 approved age... COXEN | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | NCT01631552 | Gastric Adenoca... Esophageal Canc... Hepatocellular ... Non-small Cell ... Small Cell Lung... Ovarian Epithel... Carcinoma Breas... Hormone-refract... Head and Neck C... Renal Cell Canc... Urinary Bladder... Cervical Cancer Endometrial Can... Glioblastoma Mu... Triple Negative... Pancreatic Canc... | Sacituzumab Gov... | 18 Years - | Gilead Sciences | |
| A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer | NCT05699135 | Urinary Bladder... Bladder Cancer Bladder Tumors Urothelial Carc... | Avelumab first-... | 18 Years - | Pfizer | |
| Trimodality Treatment in Bladder Cancer | NCT06395701 | Bladder Cancer Urinary Bladder... Bladder Disease | radioteraphy an... | 18 Years - 100 Years | Consorci Sanitari de Terrassa | |
| Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) | NCT03258593 | Urinary Bladder... | Durvalumab Vicineum Acetaminophen Antihistamine Bladder Biopsy TURBT Cystoscopy Urine cytology Electrocardiogr... CT MRI | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC | NCT04819399 | Urinary Bladder... | Catumaxomab | 18 Years - | Lindis Biotech GmbH | |
| A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102 | NCT04109092 | Urinary Bladder... | E7766 | 18 Years - | Eisai Inc. | |
| Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment | NCT03672240 | Non-Muscle Inva... | APL-1202 | 18 Years - 99 Years | AsierisPharma | |
| Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment | NCT00710970 | Urinary Bladder... | Tamoxifen | 18 Years - | Baylor College of Medicine | |
| Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer | NCT02381912 | Urinary Bladder... Sexual Dysfunct... Sexual Dysfunct... Erectile Dysfun... Hematuria | EORTC QLQ-C30 a... | 40 Years - | Herlev Hospital | |
| A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) | NCT01799499 | Non Muscle Inva... | TC-3 hydrogel TC-3 hydrogel TC-3 hydrogel | 21 Years - | UroGen Pharma Ltd. | |
| Virtual Histology of the Bladder Wall for Bladder Cancer Staging | NCT04369560 | Urinary Bladder... | Magnetic Resona... Gadobutrol intr... Ferumoxytol int... | 18 Years - 90 Years | University of Pittsburgh | |
| Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG) | NCT03258593 | Urinary Bladder... | Durvalumab Vicineum Acetaminophen Antihistamine Bladder Biopsy TURBT Cystoscopy Urine cytology Electrocardiogr... CT MRI | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Molecular Biosensors for Detection of Bladder Cancer | NCT02957370 | Urinary Bladder... | 18 Years - | University of California, Irvine | ||
| The Bladder Instillation Comparison Study | NCT02695771 | Urinary Bladder... | Mitomycin C Gemcitabine | 18 Years - | Spectrum Health Hospitals | |
| A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | NCT04640623 | Urinary Bladder... | TAR-200 Cetrelimab | 18 Years - | Janssen Research & Development, LLC | |
| Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients | NCT02307487 | Bladder Cancer Neoplasms Urinary Bladder... Urologic Diseas... | 120 mg MMC in 9... 140 mg MMC in 9... 160 mg MMC in 9... 120 mg MMC in 6... 140 mg MMC in 6... 160 mg MMC in 6... | 18 Years - | UroGen Pharma Ltd. | |
| A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours | NCT05397171 | Urinary Bladder... Colorectal Canc... Carcinoma, Non-... | AZD8853 Zirconium-89 cr... | 18 Years - 130 Years | AstraZeneca | |
| A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer | NCT05699135 | Urinary Bladder... Bladder Cancer Bladder Tumors Urothelial Carc... | Avelumab first-... | 18 Years - | Pfizer | |
| Effect of Pelvic Radiotherapy on the Intestinal Microbiome and Metabolome | NCT04995809 | Urinary Bladder... Uterine Cervica... Endometrial Neo... | 18 Years - | The Christie NHS Foundation Trust | ||
| SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I | NCT02254915 | Urinary Bladder... Urologic Neopla... Urogenital Neop... Neoplasms Neoplasms by Si... Urinary Bladder... Urologic Diseas... | Synergo + MMC Bacillus Calmet... | 18 Years - | Medical Enterprises Europe B.V. | |
| A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | NCT04658862 | Urinary Bladder... | Cetrelimab TAR-200 Cisplatin Gemcitabine Conventional ra... Hypo-fractioned... | 18 Years - | Janssen Research & Development, LLC | |
| CIK in Treating Patients With Bladder Cancer | NCT02489890 | Urinary Bladder... | Cytokine-induce... | 18 Years - 80 Years | The First People's Hospital of Changzhou | |
| Cystoscopic Imaging Collection and Enhancement pROject | NCT02427321 | Urinary Bladder... | Video recording... | 18 Years - | Biosignatures Limited |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
